2019 Genitourinary Cancers Symposium / ASCO GU 2019: Treatment and management of hormone-sensitive metastatic prostate cancer
2019 Genitourinary Cancers Symposium / Latest from CheckMate 650: Nivolumab plus ipilimumab for the treatment of metastatic castration-resistant prostate cancer
2019 Genitourinary Cancers Symposium /
KEYNOTE-427 cohort B: First-line pembrolizumab monotherapy for advanced non-clear cell renal cell carcinoma
2019 Genitourinary Cancers Symposium /
Outcome of men with relapses after adjuvant BEP for clinical stage I nonseminoma
2019 Genitourinary Cancers Symposium / CB-839 in combination with cabozantinib in patients with clear cell and papillary metastatic renal cell cancer
2019 Genitourinary Cancers Symposium / Updates from the BCON trial: Longterm outcomes of hypoxia modification in bladder preservation
2019 Genitourinary Cancers Symposium / Adjuvant sequential chemotherapy plus radiotherapy for LABC after radical cystectomy: Urothelial carcinoma subgroup analysis
KEYNOTE-365 Cohort A: Pembrolizumab plus olaparib in docetaxel-pretreated patients with mCRPC
CheckMate 214: Nivolumab, ipilimumab or sunitinib in patients with advanced renal cell carcinoma
ASCO GU 2019: Updates on treatment and management of bladder cancer
ASCO GU 2019: Updates on non-metastatic castration-resistant prostate cancer
STREAM trial: Enzalutamide and androgen deprivation therapy with salvage radiation in men with high-risk PSA recurrent PC
Updates on metastatic bladder cancer from ASCO GU 2019
KEYNOTE-426: Pembrolizumab and axitinib vs sunitinib in advanced renal cell carcinoma
ASCO GU 2019 renal highlights
ARCHES trial: Androgen deprivation therapy with enzalutamide or placebo in mHSPC
Updates from KEYNOTE 57: Pembrolizumab for patients with bladder cancer
Sacituzumab govitecan in patients with previously treated metastatic urothelial cancer
Whole genome and transcriptome analysis of metastatic adrenocortical carcinoma
Latest from Tivo-3: Tivozanib for refractory advanced renal cell carcinoma
2019 Genitourinary Cancers Symposium / ASCO GU 2019: Treatment and management of hormone-sensitive metastatic prostate cancer
2019 Genitourinary Cancers Symposium / Latest from CheckMate 650: Nivolumab plus ipilimumab for the treatment of metastatic castration-resistant prostate cancer
2019 Genitourinary Cancers Symposium /
KEYNOTE-427 cohort B: First-line pembrolizumab monotherapy for advanced non-clear cell renal cell carcinoma
2019 Genitourinary Cancers Symposium /
Outcome of men with relapses after adjuvant BEP for clinical stage I nonseminoma
2019 Genitourinary Cancers Symposium / CB-839 in combination with cabozantinib in patients with clear cell and papillary metastatic renal cell cancer
2019 Genitourinary Cancers Symposium / Updates from the BCON trial: Longterm outcomes of hypoxia modification in bladder preservation
2019 Genitourinary Cancers Symposium / Adjuvant sequential chemotherapy plus radiotherapy for LABC after radical cystectomy: Urothelial carcinoma subgroup analysis
KEYNOTE-365 Cohort A: Pembrolizumab plus olaparib in docetaxel-pretreated patients with mCRPC
CheckMate 214: Nivolumab, ipilimumab or sunitinib in patients with advanced renal cell carcinoma
ASCO GU 2019: Updates on treatment and management of bladder cancer
ASCO GU 2019: Updates on non-metastatic castration-resistant prostate cancer
STREAM trial: Enzalutamide and androgen deprivation therapy with salvage radiation in men with high-risk PSA recurrent PC
Updates on metastatic bladder cancer from ASCO GU 2019
KEYNOTE-426: Pembrolizumab and axitinib vs sunitinib in advanced renal cell carcinoma
ASCO GU 2019 renal highlights
ARCHES trial: Androgen deprivation therapy with enzalutamide or placebo in mHSPC
Updates from KEYNOTE 57: Pembrolizumab for patients with bladder cancer
Sacituzumab govitecan in patients with previously treated metastatic urothelial cancer
Whole genome and transcriptome analysis of metastatic adrenocortical carcinoma
Latest from Tivo-3: Tivozanib for refractory advanced renal cell carcinoma
